PREDIX II HER2: Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer (BC).

Renske Kornalijnslijper-Altena,Anne Andersson,Yvonne Brandberg,Luisa Kessler,Ellinor Elinder,Johan Hartman,Mats Hellström,Hemming Johansson,Fredrika Killander,Barbro Linderholm,Henrik Lindman,Antonios Valachis,Anna-Karin Wennstig,Hanjing Xie,Thomas Hatschek,Jonas Bergh

PREDIX II HER2: Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer (BC).

2020

Renske Kornalijnslijper-Altena
Anne Andersson
Yvonne Brandberg
Luisa Kessler
Ellinor Elinder
Johan Hartman
Mats Hellström
Hemming Johansson
Fredrika Killander
Barbro Linderholm
Henrik Lindman
Antonios Valachis
Anna-Karin Wennstig
Hanjing Xie
Thomas Hatschek
Jonas Bergh

TPS605Background: Neo-adjuvant systemic therapy (NAT) is the standard of care for most patients with early HER2-amplified and triple negative breast cancer (BC). Increasing the rate of pathological...

Keywords:

Human Epidermal Growth Factor Receptor 2
Systemic therapy
Oncology
Internal medicine
pre operative
Breast cancer
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations